A. Rachel Leheny, Ph.D.

In 2012, Dr. Leheny co-founded Valence Advantage Life Sciences. Prior to Valence Advantage, Dr. Leheny managed Caxton Advantage which she co-founded in 2004. Dr. Leheny has 30 years of experience in the life sciences industry. From April 2000 to May of 2002, Dr. Leheny was the Head of the Biotechnology Research Team and a Senior Vice President at Lehman Brothers. Dr. Leheny headed the Biotechnology Research Team at UBS Warburg and worked at Hambrecht & Quist, most recently as a Managing Director and Senior Biotechnology Analyst. Dr. Leheny was named a Wall Street Journal research All-Star for stock picking for several years. Dr. Leheny obtained her A.B. in Chemistry with honors from Harvard College and a Ph.D. in chemistry from Columbia University. She did post-doctoral work at the University of California, Berkeley where she was an NIH fellow and a lecturer. Dr. Leheny serves as Chairman of Calcimedica, Inc and previously served on the board of Anthera Pharmaceuticals and Corthera, Inc.  Dr. Leheny is currently a Director of the Clearity Foundation, a non-profit organization that provides molecular profiling for women with ovarian cancer.

Eric W. Roberts